Catalyst Event
Takeda Pharmaceutical Co Ltd (TAK) · Other
From KEDI Global Longevity Bio Index (KGLB)
6/4/2026, 12:00:00 AM
Partner Innovent Biologics announced that IBI343 (arcotatug tavatecan) met its primary endpoint in a Phase 3 trial on June 4, 2026; a medium market impact is estimated based on the clinical significance of the results. expected
Korean Translation
파트너사인 이노벤트 바이오로직스가 2026년 6월 4일 IBI343의 임상 3상 1차 평가변수 충족을 발표함. 임상적 유의성에 따라 중간 수준의 시장 영향이 예상됨.
Related Recent Events
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for a decision on the approval of the seasonal flu vaccine candidate (mRNA-1010) is scheduled for 2026-08-05, which is estimated to cause a ≥5% price impact scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer Q2 2026 earnings release on 2026-08-04; Low importance estimated as it is a routine event, scheduled
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi is scheduled to release its Q2 2026 earnings results on July 30, 2026, expected.
7/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM
GSK plc (GSK) · Earnings Release
GSK's second quarter 2026 earnings release scheduled. Routine earnings releases typically result in a price impact of approximately 1-3%.
7/28/2026, 12:00:00 AM
Revvity Inc (RVTY) · Earnings Release
Revvity's Q2 2026 earnings release is scheduled for 2026-07-27.
7/27/2026, 12:00:00 AM